PREDNISONE- prednisone tablet PREDNISONE- prednisone solution PREDNISONE INTENSOL- prednisone intensol solution, concentrate Hikma Pharmaceuticals USA Inc.

\_\_\_\_\_


PredniSONE Tablets, USP PredniSONE Oral Solution, USP PredniSONE *Intensol*™ Oral Solution (Concentrate)

Rx only

#### DESCRIPTION

Prednisone is a glucocorticoid. Glucocorticoids are adrenocortical steroids, both naturally occurring and synthetic, which are readily absorbed from the gastrointestinal tract. Prednisone, USP is a white to partially white, crystalline powder. It is very slightly soluble in water; slightly soluble in alcohol, chloroform, dioxane, and methanol.

The chemical name for prednisone is 17,21-dihydroxypregna-1,4-dienne-3,11,20-trione. The structural formula is represented below:



 $C_{21}H_{26}O_5$ 

M.W. 358.44

Each tablet, for oral administration, contains 1, 2.5, 5, 10, 20, or 50 mg of prednisone. PredniSONE Oral Solution contains 5 mg prednisone per 5 mL, and PredniSONE Intensol<sup>TM</sup> Oral Solution (Concentrate) contains 5 mg prednisone per mL.

#### Inactive Ingredients:

PredniSONE Tablets, USP contain the following inactive ingredients: lactose monohydrate, magnesium stearate, microcrystalline cellulose, pregelatinized starch, sodium starch glycolate and stearic acid (1 mg, 2.5 mg, and 5 mg only).

PredniSONE Oral Solution, USP contains alcohol 5% and the following inactive ingredients: anhydrous citric acid, edetate disodium, fructose, hydrochloric acid, maltol, peppermint oil, polysorbate 80, propylene glycol, saccharin sodium, sodium benzoate,

vanilla flavor and purified water.

PredniSONE Intensol<sup>™</sup> Oral Solution (Concentrate) contains alcohol 30% and the following inactive ingredients: anhydrous citric acid, poloxamer 188, propylene glycol and purified water.

# ACTIONS

Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have saltretaining properties, are used as replacement therapy in adrenocortical deficiency states. Their synthetic analogs are primarily used for their potent anti-inflammatory effects in disorders of many organ systems.

Glucocorticoids cause profound and varied metabolic effects. In addition, they modify the body's immune responses to diverse stimuli.

#### INDICATIONS

Prednisone tablets and solutions are indicated in the following conditions:

#### **1. Endocrine Disorders**

Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance)

Congenital adrenal hyperplasia

Hypercalcemia associated with cancer

Nonsuppurative thyroiditis

#### 2. Rheumatic Disorders

As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in:

Psoriatic arthritis

Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy)

Ankylosing spondylitis

Acute and subacute bursitis

Acute nonspecific tenosynovitis

Acute gouty arthritis

Post-traumatic osteoarthritis

Synovitis of osteoarthritis

Epicondylitis

#### 3. Collagen Diseases

During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis)

Acute rheumatic carditis

# 4. Dermatologic Diseases

Pemphigus

Bullous dermatitis herpetiformis

Severe erythema multiforme (Stevens-Johnson syndrome)

Exfoliative dermatitis

Mycosis fungoides

Severe psoriasis

Severe seborrheic dermatitis

# 5. Allergic States

Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment:

Seasonal or perennial allergic rhinitis

Bronchial asthma

Contact dermatitis

Atopic dermatitis

Serum sickness

Drug hypersensitivity reactions

# 6. Ophthalmic Diseases

Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as:

Allergic corneal marginal ulcers

Herpes zoster ophthalmicus

Anterior segment inflammation

Diffuse posterior uveitis and choroiditis

Sympathetic ophthalmia

Allergic conjunctivitis

Keratitis

Chorioretinitis

Optic neuritis Iritis and iridocyclitis

# 7. Respiratory Diseases

Symptomatic sarcoidosis

Loeffler's syndrome not manageable by other means

Berylliosis

Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy

Aspiration pneumonitis

# 8. Hematologic Disorders

Idiopathic thrombocytopenic purpura in adults

Secondary thrombocytopenia in adults

Acquired (autoimmune) hemolytic anemia

Erythroblastopenia (RBC anemia)

Congenital (erythroid) hypoplastic anemia

# 9. Neoplastic Diseases

For palliative management of:

Leukemias and lymphomas in adults

Acute leukemia of childhood

# 10. Edematous States

To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus.

# **11. Gastrointestinal Diseases**

To tide the patient over a critical period of the disease in:

Ulcerative colitis

Regional enteritis

# 12. Nervous System

Acute exacerbations of multiple sclerosis

# 13. Miscellaneous

Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy

Trichinosis with neurologic or myocardial involvement

# CONTRAINDICATIONS

Systemic fungal infections and known hypersensitivity to components.

#### WARNINGS

In patients on corticosteroid therapy subjected to unusual stress, increased dosage of rapidly acting corticosteroids before, during, and after the stressful situation is indicated.

#### Immunosuppression and Increased Risk of Infection

Corticosteroids, including prednisone, suppress the immune system and increase the risk of infection with any pathogen, including viral, bacterial, fungal, protozoan, or helminthic pathogens. Corticosteroids can:

- Reduce resistance to new infections
- Exacerbate existing infections
- Increase the risk of disseminated infections
- Increase the risk of reactivation or exacerbation of latent infections
- Mask some signs of infection

Corticosteroid-associated infections can be mild but can be severe and at times fatal. The rate of infectious complications increases with increasing corticosteroid dosages.

Monitor for the development of infection and consider prednisone withdrawal or dosage reduction as needed.

#### Tuberculosis

If prednisone is used to treat a condition in patients with latent tuberculosis or tuberculin reactivity, reactivation of tuberculosis may occur. Closely monitor such patients for reactivation. During prolonged prednisone therapy, patients with latent tuberculosis or tuberculin reactivity should receive chemoprophylaxis.

#### Varicella Zoster and Measles Viral Infections

Varicella and measles can have a serious or even fatal course in non-immune patients taking corticosteroids, including prednisone. In corticosteroid-treated patients who have not had these diseases or are non-immune, particular care should be taken to avoid exposure to varicella and measles:

- If a prednisone-treated patient is exposed to varicella, prophylaxis with varicella zoster immune globulin may be indicated. If varicella develops, treatment with antiviral agents may be considered.
- If a prednisone-treated patient is exposed to measles, prophylaxis with immunoglobulin may be indicated.

#### Hepatitis B Virus Reactivation

Hepatitis B virus reactivation can occur in patients who are hepatitis B carriers treated with immunosuppressive dosages of corticosteroids, including prednisone. Reactivation can also occur infrequently in corticosteroid-treated patients who appear to have resolved hepatitis B infection.

Screen patients for hepatitis B infection before initiating immunosuppressive (e.g., prolonged) treatment with prednisone. For patients who show evidence of hepatitis B infection, recommend consultation with physicians with expertise in managing hepatitis B regarding monitoring and consideration for hepatitis B antiviral therapy.

# **Fungal Infections**

Corticosteroids, including prednisone, may exacerbate systemic fungal infections; therefore, avoid prednisone use in the presence of such infections unless prednisone is needed to control drug reactions. For patients on chronic prednisone therapy who develop systemic fungal infections, prednisone withdrawal or dosage reduction is recommended.

# Amebiasis

Corticosteroids, including prednisone, may activate latent amebiasis. Therefore, it is recommended that latent amebiasis or active amebiasis be ruled out before initiating prednisone in patients who have spent time in the tropics or patients with unexplained diarrhea.

# Strongyloides Infestation

Corticosteroids, including prednisone, should be used with great care in patients with known or suspected Strongyloides (threadworm) infestation. In such patients, corticosteroid-induced immunosuppression may lead to Strongyloides hyperinfection and dissemination with widespread larval migration, often accompanied by severe enterocolitis and potentially fatal gram-negative septicemia.

# **Cerebral Malaria**

Avoid corticosteroids, including prednisone, in patients with cerebral malaria.

#### Kaposi's Sarcoma

Kaposi's sarcoma has been reported to occur in patients receiving corticosteroid therapy, most often for chronic conditions. Discontinuation of corticosteroids may result in clinical improvement of Kaposi's sarcoma.

#### Usage in pregnancy

Since adequate human reproduction studies have not been done with corticosteroids, the use of these drugs in pregnancy, nursing mothers or women of child-bearing potential requires that the possible benefits of the drug be weighed against the potential hazards to the mother and embryo or fetus. Infants born of mothers who have received substantial doses of corticosteroids during pregnancy, should be carefully observed for signs of hypoadrenalism.

Average and large doses of hydrocortisone or cortisone can cause elevation of blood pressure, salt and water retention, and increased excretion of potassium. These effects are less likely to occur with the synthetic derivatives except when used in large doses. Dietary salt restriction and potassium supplementation may be necessary. All corticosteroids increase calcium excretion.

# While on corticosteroid therapy patients should not be vaccinated against smallpox. Other immunization procedures should not be undertaken in

# patients who are on corticosteroids, especially on high dose, because of possible hazards of neurological complications and a lack of antibody response.

Prolonged use of corticosteroids may produce posterior subcapsular cataracts, glaucoma with possible damage to the optic nerves, and may enhance the establishment of secondary ocular infections due to fungi or viruses.

# PRECAUTIONS

#### **General Precautions**

Drug-induced secondary adrenocortical insufficiency may be minimized by gradual reduction of dosage. This type of relative insufficiency may persist for months after discontinuation of therapy; therefore, in any situation of stress occurring during that period, hormone therapy should be reinstituted. Since mineralocorticoid secretion may be impaired, salt and/or a mineralocorticoid should be administered concurrently.

There is an enhanced effect of corticosteroids on patients with hypothyroidism and in those with cirrhosis.

Corticosteroids should be used cautiously in patients with ocular herpes simplex because of possible corneal perforation.

The lowest possible dose of corticosteroid should be used to control the condition under treatment, and when reduction in dosage is possible, the reduction should be gradual.

Psychic derangements may appear when corticosteroids are used, ranging from euphoria, insomnia, mood swings, personality changes, and severe depression, to frank psychotic manifestations. Also, existing emotional instability or psychotic tendencies may be aggravated by corticosteroids.

Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia.

Steroids should be used with caution in nonspecific ulcerative colitis, if there is a probability of impending perforation, abscess or other pyogenic infection; diverticulitis; fresh intestinal anastomoses; active or latent peptic ulcer; renal insufficiency; hypertension; osteoporosis; and myasthenia gravis.

Growth and development of infants and children on prolonged corticosteroid therapy should be carefully observed.

Although controlled clinical trials have shown corticosteroids to be effective in speeding the resolution of acute exacerbations of multiple sclerosis, they do not show that corticosteroids affect the ultimate outcome or natural history of the disease. The studies do show that relatively high doses of corticosteroids are necessary to demonstrate a significant effect (see DOSAGE AND ADMINISTRATION).

Since complications of treatment with glucocorticoids are dependent on the size of the dose and the duration of treatment, a risk/benefit decision must be made in each individual case as to dose and duration of treatment and as to whether daily or intermittent therapy should be used.

Convulsions have been reported with concurrent use of methylprednisolone and

cyclosporin. Since concurrent use of these agents results in a mutual inhibition of metabolism, it is possible that adverse events associated with the individual use of either drug may be more apt to occur.

# **ADVERSE REACTIONS**

#### Fluid and Electrolyte Disturbances

- Sodium retention Fluid retention
- Congestive heart failure in susceptible patients
- Potassium loss
- Hypokalemic alkalosis
- Hypertension

# Musculoskeletal

Muscle weakness Steroid myopathy Loss of muscle mass Osteoporosis Tendon rupture, particularly of the Achilles tendon Vertebral compression fractures Aseptic necrosis of femoral and humeral heads Pathologic fracture of long bones

# Gastrointestinal

- Peptic ulcer with possible perforation and hemorrhage Pancreatitis Abdominal distention Ulcerative esophagitis **Dermatologic**
- Impaired wound healing Thin fragile skin Petechiae and ecchymoses Facial erythema Increased sweating May suppress reactions to skin tests

- ..

#### Metabolic

Negative nitrogen balance due to protein catabolism

#### Neurological

Increased intracranial pressure with papilledema (pseudotumor cerebri) usually after treatment

Convulsions

Vertigo

Headache

# Endocrine

Menstrual irregularities

Development of Cushingoid state

Secondary adrenocortical and pituitary unresponsiveness, particularly in times of stress, as in trauma, surgery or illness

Suppression of growth in children

Decreased carbohydrate tolerance

Manifestations of latent diabetes mellitus

Increased requirements for insulin or oral hypoglycemic agents in diabetics

# Ophthalmic

Posterior subcapsular cataracts

Increased intraocular pressure

Glaucoma

Exophthalmos

# Additional Reactions

Urticaria and other allergic, anaphylactic or hypersensitivity reactions

# DOSAGE AND ADMINISTRATION

The initial dosage of prednisone may vary from 5 mg to 60 mg of prednisone per day depending on the specific disease entity being treated. In situations of less severity lower doses will generally suffice while in selected patients higher initial doses may be required. The initial dosage should be maintained or adjusted until a satisfactory response is noted. If after a reasonable period of time there is a lack of satisfactory clinical response, prednisone should be discontinued and the patient transferred to other appropriate therapy. **IT SHOULD BE EMPHASIZED THAT DOSAGE REQUIREMENTS ARE VARIABLE AND MUST BE INDIVIDUALIZED ON THE BASIS OF THE DISEASE UNDER TREATMENT AND THE RESPONSE OF THE PATIENT.** 

After a favorable response is noted, the proper maintenance dosage should be determined by decreasing the initial drug dosage in small decrements at appropriate time intervals until the lowest dosage which will maintain an adequate clinical response is reached. It should be kept in mind that constant monitoring is needed in regard to drug dosage. Included in the situations which may make dosage adjustments necessary are changes in clinical status secondary to remissions or exacerbations in the disease process, the patient's individual drug responsiveness, and the effect of patient exposure to stressful situations not directly related to the disease entity under treatment; in this latter situation it may be necessary to increase the dosage of prednisone for a period of time consistent with the patient's condition. If after long-term therapy the drug is to be stopped, it is recommended that it be withdrawn gradually rather than abruptly.

# **Multiple Sclerosis**

In the treatment of acute exacerbations of multiple sclerosis daily doses of 200 mg of prednisolone for a week followed by 80 mg every other day for 1 month have been shown to be effective. (Dosage range is the same for prednisone and prednisolone.)

# ADT<sup>®</sup> (Alternate Day Therapy)

ADT is a corticosteroid dosing regimen in which twice the usual daily dose of corticoid is administered every other morning. The purpose of this mode of therapy is to provide the patient requiring long-term pharmacologic dose treatment with the beneficial effects of corticoids while minimizing certain undesirable effects, including pituitary-adrenal suppression, the Cushingoid state, corticoid withdrawal symptoms, and growth suppression in children.

The rationale for this treatment schedule is based on two major premises: (a) the antiinflammatory or therapeutic effect of corticoids persists longer than their physical presence and metabolic effects and (b) administration of the corticosteroid every other morning allows for re-establishment of more nearly normal hypothalamic-pituitaryadrenal (HPA) activity on the off-steroid day.

A brief review of the HPA physiology may be helpful in understanding this rationale. Acting primarily through the hypothalamus a fall in free cortisol stimulates the pituitary gland to produce increasing amounts of corticotropin (ACTH) while a rise in free cortisol inhibits ACTH secretion. Normally the HPA system is characterized by diurnal (circadian) rhythm. Serum levels of ACTH rise from a low point about 10 pm to a peak level about 6 am. Increasing levels of ACTH stimulate adrenocortical activity resulting in a rise in plasma cortisol with maximal levels occurring between 2 am and 8 am. This rise in cortisol dampens ACTH production and in turn adrenocortical activity. There is a gradual fall in plasma corticoids during the day with lowest levels occurring about midnight.

The diurnal rhythm of the HPA axis is lost in Cushing's disease, a syndrome of adrenocortical hyperfunction characterized by obesity with centripetal fat distribution, thinning of the skin with easy bruisability, muscle wasting with weakness, hypertension, latent diabetes, osteoporosis, electrolyte imbalance, etc. The same clinical findings of hyperadrenocorticism may be noted during long-term pharmacologic dose corticoid therapy administered in conventional daily divided doses. It would appear, then, that a disturbance in the diurnal cycle with maintenance of elevated corticoid values during the night may play a significant role in the development of undesirable corticoid effects. Escape from these constantly elevated plasma levels for even short periods of time may be instrumental in protecting against undesirable pharmacologic effects.

During conventional pharmacologic dose corticosteroid therapy, ACTH production is inhibited with subsequent suppression of cortisol production by the adrenal cortex. Recovery time for normal HPA activity is variable depending upon the dose and duration of treatment. During this time the patient is vulnerable to any stressful situation. Although it has been shown that there is considerably less adrenal suppression following a single morning dose of prednisolone (10 mg) as opposed to a quarter of that dose administered every 6 hours, there is evidence that some suppressive effect on adrenal activity may be carried over into the following day when pharmacologic doses are used. Further, it has been shown that a single dose of certain corticosteroids will produce adrenocortical suppression for two or more days. Other corticoids, including methylprednisolone, hydrocortisone, prednisone, and prednisolone, are considered to be short acting (producing adrenocortical suppression for  $1\frac{1}{4}$  to  $1\frac{1}{2}$  days following a single dose) and thus are recommended for alternate day therapy.

The following should be kept in mind when considering alternate day therapy:

- 1) Basic principles and indications for corticosteroid therapy should apply. The benefits of ADT should not encourage the indiscriminate use of steroids.
- 2) ADT is a therapeutic technique primarily designed for patients in whom long-term pharmacologic corticoid therapy is anticipated.
- 3) In less severe disease processes in which corticoid therapy is indicated, it may be possible to initiate treatment with ADT. More severe disease states usually will require daily divided high dose therapy for initial control of the disease process. The initial suppressive dose level should be continued until satisfactory clinical response is obtained, usually four to ten days in the case of many allergic and collagen diseases. It is important to keep the period of initial suppressive dose as brief as possible particularly when subsequent use of alternate day therapy is intended. Once control has been established, two courses are available: (a) change to ADT and then gradually reduce the amount of corticoid given every other day or (b) following control of the disease process reduce the daily dose of corticoid to the lowest effective level as rapidly as possible and then change over to an alternate day schedule. Theoretically, course (a) may be preferable.
- 4) Because of the advantages of ADT, it may be desirable to try patients on this form of therapy who have been on daily corticoids for long periods of time (e.g., patients with rheumatoid arthritis). Since these patients may already have a suppressed HPA axis, establishing them on ADT may be difficult and not always successful. However, it is recommended that regular attempts be made to change them over. It may be helpful to triple or even quadruple the daily maintenance dose and administer this every other day rather than just doubling the daily dose if difficulty is encountered. Once the patient is again controlled, an attempt should be made to reduce this dose to a minimum.
- 5) As indicated above, certain corticosteroids, because of their prolonged suppressive effect on adrenal activity, are not recommended for alternate day therapy (e.g., dexamethasone and betamethasone).
- 6) The maximal activity of the adrenal cortex is between 2 am and 8 am, and it is minimal between 4 pm and midnight. Exogenous corticosteroids suppress adrenocortical activity the least, when given at the time of maximal activity (am).
- 7) In using ADT it is important, as in all therapeutic situations to individualize and tailor the therapy to each patient. Complete control of symptoms will not be possible in all

patients. An explanation of the benefits of ADT will help the patient to understand and tolerate the possible flare-up in symptoms which may occur in the latter part of the off-steroid day. Other symptomatic therapy may be added or increased at this time if needed.

- 8) In the event of an acute flare-up of the disease process, it may be necessary to return to a full suppressive daily divided corticoid dose for control. Once control is again established alternate day therapy may be re-instituted.
- 9) Although many of the undesirable features of corticosteroid therapy can be minimized by ADT, as in any therapeutic situation, the physician must carefully weigh the benefit-risk ratio for each patient in whom corticoid therapy is being considered.

#### HOW SUPPLIED

#### PredniSONE Tablets, USP

1 mg - White to off-white, round, biconvex tablet; scored on one side and product identification "54 [above] 092" debossed on the other side.

NDC 0054-8739-25: 10x10 Unit-Dose

NDC 0054-4741-25: Bottle of 100 Tablets

NDC 0054-4741-31: Bottle of 1,000 Tablets

2.5 mg - White to off-white, round, biconvex tablet; scored on one side and product identification "54 [above] 339" debossed on the other side.

NDC 0054-8740-25: 10x10 Unit-Dose

NDC 0054-4742-25: Bottle of 100 Tablets

5 mg - White to off-white, round, biconvex tablet; scored on one side and product identification "54 [above] 612" debossed on the other side.

NDC 0054-8724-25: 10x10 Unit-Dose

NDC 0054-4728-25: Bottle of 100 Tablets

NDC 0054-4728-31: Bottle of 1,000 Tablets

10 mg - White to off-white, round, biconvex tablet; scored on one side and product identification "54 [above] 899" debossed on the other side.

NDC 0054-0017-20: 10x10 Unit-Dose

NDC 0054-0017-25: Bottle of 100 Tablets

NDC 0054-0017-29: Bottle of 500 Tablets

# 20 mg - White to off-white, round, biconvex tablet; scored on one side and product identification "54 [above] 760" debossed on the other side.

NDC 0054-0018-20: 10x10 Unit-Dose

NDC 0054-0018-25: Bottle of 100 Tablets

NDC 0054-0018-29: Bottle of 500 Tablets

# 50 mg - White to off-white, round, biconvex tablet; scored on one side and product identification "54 [above] 343" debossed on the other side.

NDC 0054-0019-20: 10x10 Unit-Dose

NDC 0054-0019-25: Bottle of 100 Tablets

Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]

Dispense in a tight, child-resistant container as defined in the USP/NF.

PROTECT FROM MOISTURE.

# PredniSONE Oral Solution USP, 5 mg per 5 mL

# Clear, colorless, slightly viscous solution.

NDC 0054-3722-50: Bottle of 120 mL

NDC 0054-3722-63: Bottle of 500 mL

Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]

Dispense in a tight, light-resistant, child-resistant container as defined in the USP/NF.

# PredniSONE Intensol<sup>™</sup> Oral Solution (Concentrate), 5 mg per mL

# Clear, colorless, slightly viscous solution.

NDC 0054-3721-44: Bottle of 30 mL with calibrated oral syringe (graduations of 0.25 mL [1.25 mg] to 1 mL [5 mg] on the syringe)

Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]

Dispense only in the bottle and only with the calibrated oral syringe provided.


Discard opened bottle after 90 days.

Distributed by: **Hikma Pharmaceuticals USA Inc.** Berkeley Heights, NJ 07922

C50000278/04-k02 Revised February 2024

# PACKAGE/LABEL PRINCIPAL DISPLAY PANEL


NDC 0054-**8739**-25 10x10 Unit-Dose Tablets **PredniSONE Tablets, USP 1 mg** 



NDC 0054-4741-25 100 Tablets PredniSONE Tablets, USP 1 mg




NDC 0054-**8740**-25 10x10 Unit-Dose Tablets PredniSONE Tablets, USP 2.5 mg



NDC 0054-4742-25 100 Tablets PredniSONE Tablets, USP 2.5 mg



NDC 0054-8724-25 10x10 Unit-Dose Tablets PredniSONE Tablets, USP 5 mg




NDC 0054-**4728**-25 100 Tablets PredniSONE Tablets, USP 5 mg



#### PACKAGE/LABEL PRINCIPAL DISPLAY PANEL


NDC 0054-**0017**-20 10x10 Unit-Dose Tablets **PredniSONE Tablets**, **USP 10 mg** 



NDC 0054-0017-25 100 Tablets PredniSONE Tablets, USP 10 mg




NDC 0054-0018-20 10x10 Unit-Dose Tablets PredniSONE Tablets, USP 20 mg



NDC 0054-0018-25 100 Tablets PredniSONE Tablets, USP 20 mg



NDC 0054-0019-20 10x10 Unit-Dose Tablets PredniSONE Tablets, USP 50 mg



NDC 0054-0019-25 100 Tablets PredniSONE Tablets, USP 50 mg



NDC 0054-**3722**-50 120 mL PredniSONE Oral Solution, USP 5 mg per 5 mL

NDC 0054-3722-50 120 mL PredniSONE Oral Solution, USP	prednisone, USP, alcohol 5%. Ickage Insert for formation. -resistant, child-resistant he USP/NF. * to 77°F).	LOT EXP.	2-50 7
5 mg per 5 mL	Roc Roc Roc Roc Roc		0 5 4 - 3 7 2
Distributed by: <b>Hikma</b> R <sub>x</sub> only Pharmaceuticals USA Inc. Berkeley Heights, NJ 07922	Each 5 mL contains 5 USUAL DOSAGE: Se Complete Prescribin Dispense in a tight, li container as defined Store at 20° to 25°C [See USP Controlled		c50000266/02

NDC 0054-**3721**-44 30 mL **PredniSONE** *Intensol*<sup>™</sup> **Oral Solution (Concentrate) 5 mg per mL** 



Route of Administration ORAL   Active Ingredient/Active Moiety   Ingredient Name   Basis of Strength   PREDNISONE (UNII: VB0R961HZT) (PREDNISONE - UNII:VB0R961HZT)   PREDNISONE (UNII: VB0R961HZT) (PREDNISONE - UNII:VB0R961HZT)   PREDNISONE (UNII: VB0R961HZT)					REDNISONE ednisone tablet
Route of Administration ORAL     Active Ingredient/Active Moiety   Ingredient Name Basis of Strength   PREDNISONE (UNII: VB0R961HZT) (PREDNISONE - UNII:VB0R961HZT) PREDNISONE   Inactive Ingredients   Ingredient Name Ingredient Name   Ingredient Name   Ingredient Name Ingredient Name					roduct Information
Active Ingredient/Active Moiety Ingredient Name Basis of Strength PREDNISONE (UNII: VB0R961HZT) (PREDNISONE - UNII:VB0R961HZT) PREDNISONE Inactive Ingredients Ingredient Name LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X) MAGNESIUM STEARATE (UNII: 70097M6I30) MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)	DC:0054-4741	ode (Source) ND	Ite	HUMAN PRESCRIPTION DRUG	roduct Type
Ingredient Name       Basis of Strength         PREDNISONE (UNII: VB0R961HZT) (PREDNISONE - UNII:VB0R961HZT)       PREDNISONE         Inactive Ingredients       Ingredient Name         LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X)       MAGNESIUM STEARATE (UNII: 70097M6I30)         MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)       Ingredient)				ORAL	oute of Administration
Ingredient Name       Basis of Strength         PREDNISONE (UNII: VB0R961HZT) (PREDNISONE - UNII:VB0R961HZT)       PREDNISONE         Inactive Ingredients       Ingredient Name         LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X)       MAGNESIUM STEARATE (UNII: 70097M6I30)         MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)       Ingredient)					
PREDNISONE (UNII: VB0R961HZT) (PREDNISONE - UNII:VB0R961HZT)       PREDNISONE         Inactive Ingredients       Ingredient Name         LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X)       MAGNESIUM STEARATE (UNII: 70097M6I30)         MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)       Ingredient Name				Moiety	ctive Ingredient/Active
Inactive Ingredients Ingredient Name LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X) MAGNESIUM STEARATE (UNII: 70097M6I30) MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)	n Strength	<b>Basis of Strength</b>		dient Name	Ingre
Ingredient Name         LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X)         MAGNESIUM STEARATE (UNII: 70097M6I30)         MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)	1 mg	PREDNISONE	T)	(PREDNISONE - UNII:VB0R961HZT)	EDNISONE (UNII: VB0R961HZT)
Ingredient Name         LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X)         MAGNESIUM STEARATE (UNII: 70097M6I30)         MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)					
LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X) MAGNESIUM STEARATE (UNII: 70097M6I30) MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)					active Ingredients
MAGNESIUM STEARATE (UNII: 70097M6I30) MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)	Strength			Ingredient Name	
MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)				EWQ57Q8I5X)	CTOSE MONOHYDRATE (UNII:
				097M6I30)	AGNESIUM STEARATE (UNII: 70
				: (UNII: OP1R32D61U)	CROCRYSTALLINE CELLULOS
STARCH, CURN (UNII: 08232NT35J)				J)	ARCH, CORN (UNII: 08232NY35
SODIUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856J3G2A2)			42)	(PE A POTATO (UNII: 5856J3G2A2	DIUM STARCH GLYCOLATE T
STEARIC ACID (UNII: 4ELV7Z65AP)					EARIC ACID (UNII: 4ELV7Z65AP

Ρ	roduct Char	acteristi	ics			
Color		WHITE	Score		2 pieces	
Shape		ROUND	Size		6mm	
Flavor			Imprint Code		54092	
Co	ontains					
_						
Pa	ackaging					
#	Item Code		Package Description		Marketing Start Date	Marketing End Date
1	NDC:0054- 4741-25	100 in 1 BC Combinatio	OTTLE, PLASTIC; Type on Product	e 0: Not a	04/22/1982	
2	NDC:0054- 4741-31	1000 in 1 B Combinatio	OTTLE, PLASTIC; Typ on Product	; Type 0: Not a 04/22/1982		
Μ	larketing	Inform	nation			
Marketing Applicat Category		lication Number ( Citatior		Marketing Start Date	Marketing End Date	
ANDA ANDA080		30352		04/22/1982		

<b>PREDNISONE</b> prednisone tablet						
Product Information						
Product Type	HUMAN PRESCR	RIPTION DRUG	ltem C	ode (Source)	NDC:	0054-4742
Route of Administration	ORAL					
Active Ingredient/Activ	e Moiety					
Ing	redient Name			Basis of Stre	ength	Strength
PREDNISONE (UNII: VB0R961HZ	T) (PREDNISONE -	UNII:VB0R961HZT)		PREDNISONE	_	2.5 mg
Inactive Ingredients						
	Ingredier	nt Name				Strength
LACTOSE MONOHYDRATE (UN	I: EWQ57Q8I5X)					
MAGNESIUM STEARATE (UNII:	70097M6I30)					
MICROCRYSTALLINE CELLULO	· · · ·	D61U)				
STARCH, CORN (UNII: 08232NY)	-					
SODIUM STARCH GLYCOLATE		(UNII: 5856J3G2A2)				
STEARIC ACID (UNII: 4ELV7Z65A	AP)					
<b>Product Characteristics</b>	5					
Color W	HITE	Score		2	2 pieces	

Sł	аре		ROUND	Size			6mm
Fla	avor			Impri	nt Code		54;339
Co	ontains						
Pa	ackaging						
#	ltem Code		Package	Description	n	Marketing Start Date	Marketing End Date
		100 in 1 BC Combinatio	TTLE, PLASTIC; Type 0: Not a n Product		04/22/1982		
Μ	arketing	Inform	ation				
	Marketing Category	Арр		umber or Mo Citation	nograph	Marketing Start Date	Marketing End Date
AN	DA	ANDA08	80352			04/22/1982	

PREDNISONE						
prednisone tablet						
Product Information						
Product Type	HUMAN PR	ESCRIPTION DRUG	Item C	ode (Source)	NDC	:0054-4728
Route of Administration	ORAL					
Active Ingredient/Activ	ve Moiety					
Ing	gredient Na	me		Basis of Str	ength	Strength
PREDNISONE (UNII: VB0R961H	ZT) (PREDNISO	NE - UNII:VB0R961HZT)		PREDNISONE		5 mg
Inactive Ingredients						
	Ingre	dient Name				Strength
LACTOSE MONOHYDRATE (UI	NII: EWQ57Q8I5	X)				
MAGNESIUM STEARATE (UNII:						
MICROCRYSTALLINE CELLUL		R32D61U)				
STARCH, CORN (UNII: 08232N)	-					
SODIUM STARCH GLYCOLATE		<b>ATO</b> (UNII: 5856J3G2A2)				
STEARIC ACID (UNII: 4ELV7Z65	5AP)					
<b>Product Characteristic</b>	s					
Color	WHITE	Score		2	2 pieces	
Shape	ROUND	Size		E	6mm	
Flavor		Imprint Code		5	54:612	
		imprint couc				

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
		100 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product	04/21/1972	
/	NDC:0054- 4728-31	1000 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product	04/21/1972	
	4720-31			
	arketing	Information		
			Marketing Start Date	Marketing End Date
M	arketing Marketing	Information Application Number or Monograph	-	Marketing End Date

 prednisone tablet

 Product Information

 Product Type
 HUMAN PRESCRIPTION DRUG
 Item Code (Source)
 NDC:0054-0017

 Route of Administration
 ORAL
 VIC:0054-0017

Active Ingredient/Active Moiety						
Ingredient Name	<b>Basis of Strength</b>	Strength				
PREDNISONE (UNII: VB0R961HZT) (PREDNISONE - UNII:VB0R961HZT)	PREDNISONE	10 mg				

#### **Inactive Ingredients**

-	
Ingredient Name	Strength
LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X)	
MAGNESIUM STEARATE (UNII: 70097M6I30)	
MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)	
STARCH, CORN (UNII: 08232NY3SJ)	
SODIUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856J3G2A2)	

<b>Product Charac</b>	teristics			
Color	WHITE	Score		2 pieces
Shape	ROUND	Size	(	6mm
Flavor		Imprint Code	<u>.</u>	54;899
Contains				
Packaging				
# Item Code	Package D	escription	Marketing Start Date	Marketing End Date

1	NDC:0054- 0017-25	100 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product	02/13/2003	
2	NDC:0054- 0017-29	500 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product	02/13/2003	
3	NDC:0054- 0017-20	10 in 1 CARTON	02/13/2003	
3		10 in 1 BLISTER PACK; Type 0: Not a Combination Product		
M	larketing	Information		
	Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
AN	IDA	ANDA080352	02/13/2003	

PREDNISON	E									
prednisone tablet										
Product Inform	mation									
Product Type	HUMAN PRESCRIPTION DRUG Item Code (Source)						:0054-0018			
Route of Adminis	•									
Active Ingredia	ent/Active	Moiety								
Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength										
PREDNISONE (UNII:	-		UNIII·VB0B961H7T)		PREDNISONE	rengtii	20 mg			
	VBORGOINZ I)				THE DIS ONE		20 mg			
Inactive Ingree	dients									
		Ingredier	nt Name				Strength			
LACTOSE MONOHY	(DRATE (UNII:	EWQ57Q8I5X)								
MAGNESIUM STEA	RATE (UNII: 70	097M6I30)								
MICROCRYSTALLIN	IE CELLULOSE	E (UNII: OP1R32D	061U)							
STARCH, CORN (UN	III: 08232NY35	J)								
SODIUM STARCH G	LYCOLATE T	ΥΡΕ Α ΡΟΤΑΤΟ	(UNII: 5856J3G2A2)							
Product Chara	ctoristics									
Color	WHI	TE	Score			2 pieces				
Shape	ROL		Size			9mm				
Flavor			Imprint Code			54;760				
Contains			• • • • • •							
Packaging										
# Item Code	Pa	ackage Desci	ription	Ма	rketing Start		eting End			
					Date		Date			

M	larketing Marketing Category	Information Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
M	larketing	Information		
		- Todaec		
3		10 in 1 BLISTER PACK; Type 0: Not a Combination Product		
3	NDC:0054- 0018-20	10 in 1 CARTON	02/13/2003	
2	NDC:0054- 0018-29	500 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product	02/13/2003	
	0018-25	Combination Product	02/13/2003	

PREDNISONE						
prednisone tablet						
<b>Product Information</b>						
Product Type	HUMAN P	PRESCRIPTION DRUG	Item C	ode (Source)	NDC	:0054-0019
Route of Administration	ORAL					
Active Ingredient/Act	ive Moiety					
Ir	gredient Na	ame		Basis of Str	rength	Strength
PREDNISONE (UNII: VB0R961	HZT) (PREDNIS	ONE - UNII:VB0R961HZT)		PREDNISONE		50 mg
Inactive Ingredients						
	Ingr	edient Name				Strength
LACTOSE MONOHYDRATE (	UNII: EWQ57Q8	I5X)				
MAGNESIUM STEARATE (UN	II: 70097M6I30)					
MICROCRYSTALLINE CELLU	LOSE (UNII: OF	P1R32D61U)				
STARCH, CORN (UNII: 08232						
SODIUM STARCH GLYCOLA	TE TYPE A PO	<b>TATO</b> (UNII: 5856J3G2A2)	)			
Product Characterist	ics					
Color	WHITE	Score			2 pieces	
Shape	ROUND	Size			10mm	
Flavor		Imprint Code			54;343	
Contains						
Packaging						
# Item Code	Package l	Description	Mar	keting Start Date	Mark	eting End Date

Marketing Marketing Category	Information Application Number or Monograph Citation	Marketing Start Date	Marketing End Date					
Marketing	Information							
Marketing Information								
<b>2</b> NDC:0054- 0019-25	100 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product	03/14/2003						
1	10 in 1 BLISTER PACK; Type 0: Not a Combination Product							
0019-20	10 in 1 CARTON	03/14/2003						

<b>PREDNISONE</b> prednisone solution						
Product Informatio	n					
Product Type		HUMAN PRESCRIPTION DRUG	ltom	Code (Source)		C:0054-3722
		ORAL	item	code (Source)		2.0031 3722
Route of Administratio	on	UKAL				
Active Ingredient/A	ctive	Moiety				
	Ingred	ient Name		Basis of Streng	yth	Strength
PREDNISONE (UNII: VB0R96	61HZT)	(PREDNISONE - UNII:VB0R961HZT)		PREDNISONE		5 mg in 5 mL
Inactive Ingredients	S					
		Ingredient Name			S	trength
ALCOHOL (UNII: 3K9958V90						
ANHYDROUS CITRIC ACID	-	· ·				
EDETATE DISODIUM (UNII:		.C86K)				
FRUCTOSE (UNII: 6YSS42V						
HYDROCHLORIC ACID (UN		7582CB)				
MALTOL (UNII: 3A9RD92BS4						
PEPPERMINT OIL (UNII: AV						
POLYSORBATE 80 (UNII: 6						
PROPYLENE GLYCOL (UNII						
SACCHARIN SODIUM (UNII						
SODIUM BENZOATE (UNII:	-	=5EU)				
WATER (UNII: 059QF0K00R)	.)					
Packaging						
# Item Code	Pao	kage Description	Ma	rketing Start Date	Marl	ceting End Date
<b>1</b> NDC:0054-3722- 63 Product		TTLE; Type 0: Not a Combination	11/08	/1984		

<b>2</b> NDC:0054-3722- 50	120 mL in 1 BOTTLE; Type 0: Not a Combination Product	12/13/1996	
Marketing	Information		
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA088703	11/08/1984	

<b>PREDNISO</b> prednisone inte						
Product Info	ormation					
Product Type		HUMAN PRESCRIPTION DRUG	ltem	Code (Source)	ND	C:0054-3721
Route of Admi	nistration	ORAL				
Active Ingree	dient/Active	Moiety				
	Ingred	lient Name		Basis of Streng	yth	Strength
PREDNISONE (UN	NII: VBOR961HZT)	(PREDNISONE - UNII:VB0R961HZT)		PREDNISONE		5 mg in 1 mL
Inactive Ingr	redients					
		Ingredient Name			S	Strength
ALCOHOL (UNII: 3	•					
ANHYDROUS CIT	-	-				
POLOXAMER 188		•				
PROPYLENE GLY	-	Q167V3)				
WATER (UNII: 059	9QF0KO0R)					
Packaging						
# Item Code	Pa	ackage Description	I	Marketing Start Date	Ма	rketing End Date
<b>1</b> NDC:0054- 3721-44	30 mL in 1 BOT of Co-Package	FLE, GLASS; Type 1: Convenience K	Cit 0	2/20/1985		
Marketing	Informat	ion				
Marketing	Applica	tion Number or Monograph	м	arketing Start	Ма	rketing End

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA088810	02/20/1985	

PREDNISONE

Ρ	roduct Info	rmation						
Pı	oduct Type		HUMAN F	RESCRIPTION DRUG	ltem Co	de (Source)	NDC	:0054-8739
	oute of Admin	istration	ORAL					
4	tive Ingred	ient/Activ	ve Moiety					
		Ing	gredient Na	ame		Basis of Str	ength	Strengt
PR	EDNISONE (UNI	I: VB0R961H	ZT) (PREDNIS	ONE - UNII:VB0R961HZT)	Р	REDNISONE		1 mg
In	active Ingre	edients						
			-	edient Name				Strength
	AGNESIUM STE							
				1R32D61U)				
	ARCH, CORN (L							
SODIUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856J3G2A2)								
ст				<b>IAIO</b> (UNII: 5856J3G2A2	)			
sт	EARIC ACID (UN	NII: 4ELV7Z65		TATO (UNII: 5856J3G2A2	,			
			5AP)	TATO (UNII: 5856)3GZAZ	,			
P	roduct Char	acteristi	5AP) C <b>S</b>					
Pı Ca	roduct Char	acteristi	5AP) C <b>S</b> WHITE	Score			2 pieces	
Pı Ca Sł	r <b>oduct Char</b> Nor Nape	acteristi	5AP) C <b>S</b>	Score Size			6mm	
Pi Ca Sh	r <b>oduct Char</b> blor ape avor	acteristi	5AP) C <b>S</b> WHITE	Score				
Pi Ca Sh	r <b>oduct Char</b> Nor Nape	acteristi	5AP) C <b>S</b> WHITE	Score Size			6mm	
P C S F I C C	r <b>oduct Char</b> olor nape avor ontains	acteristi	5AP) C <b>S</b> WHITE	Score Size			6mm	
Pi Si Fi Ca	r <b>oduct Char</b> blor ape avor	acteristi	5AP) CS WHITE ROUND	Score Size	Marke	eting Start	6mm 54092 Mark	-
Pi Ca Sh Fli Ca Pi	roduct Char plor ape avor ontains ackaging Item Code NDC:0054-	acteristi	5AP) CS WHITE ROUND Package I	Score Size Imprint Code	Marke	eting Start Date	6mm 54092 Mark	eting End Date
Pi Ca Sh Fli Ca Pi #	roduct Char olor ape avor ontains ackaging Item Code	acteristic	5AP) CS WHITE ROUND Package I	Score Size Imprint Code	<b>Marke</b> 04/22/198	eting Start Date	6mm 54092 Mark	eting End Date
Pi Ca Fli Ca	roduct Char plor ape avor ontains ackaging Item Code NDC:0054-	acteristic	5AP) CS WHITE ROUND Package I	Score Size Imprint Code	<b>Marke</b> 04/22/198	eting Start Date	6mm 54092 Mark	-
Pi Co Sh Fli Co Pi 1	roduct Char olor ape avor ontains ackaging Item Code NDC:0054- 8739-25	acteristic	5AP) CS WHITE ROUND Package I RTON STER PACK; Ty	Score Size Imprint Code	<b>Marke</b> 04/22/198	eting Start Date	6mm 54092 Mark	-
Pi Co Sh Fli Co Pi 4	roduct Char olor ape avor ontains ackaging Item Code NDC:0054- 8739-25	acteristic 10 in 1 CAR 10 in 1 BLIS Product	SAP) CS WHITE ROUND Package I RTON STER PACK; Ty ation	Score Size Imprint Code	<b>Marke</b> 04/22/198	eting Start Date 82	6mm 54092 Mark	Date
Pi Cc Sh Fla Cc Pa # 1	roduct Char olor ape avor ontains ackaging Item Code NDC:0054- 8739-25	acteristic 10 in 1 CAR 10 in 1 BLIS Product	5AP) CS WHITE ROUND Package I RTON STER PACK; Ty ation ication Num	Score Size Imprint Code	<b>Marke</b> 04/22/198	eting Start Date	6mm 54092 Mark	-

**PREDNISONE** prednisone tablet

Product Ty		ion						
FIGUACETy	уре		HUMAN PRES	CRIPTION DRUG	ltem Co	de (Source)	NDC	:0054-8740
Route of Administration ORAL								
Active In	grealent/		-					
	Ingredient Name Basis of Strength EDNISONE (UNII: VB0R961HZT) (PREDNISONE - UNII:VB0R961HZT) PREDNISONE					ength	Strengt	
PREDNISON	E (UNII: VBOI	R961HZT)	(PREDNISONE	- UNII:VB0R961H21)	ŀ	REDNISONE		2.5 mg
Inactive I	ngredier	nts						
			Ingredie	ent Name				Strength
		-	EWQ57Q8I5X)					
MAGNESIUM		•	· ·					
			(UNII: OP1R32	2D61U)				
STARCH, CO								
SODIUM STA				<b>D</b> (UNII: 5856J3G2A2)				
	Characte		rr.	C a a ma		2	nincon	
Color	Characte	WHI	_	Score			pieces	
Color Shape	Characte		_	Size		6	imm	
Color Shape Flavor	Characte	WHI	_			6	-	
Color Shape Flavor	Characte	WHI	_	Size		6	imm	
Color Shape Flavor Contains		WHI	_	Size		6	imm 94;339	
Color Shape Flavor Contains <b>Packagin</b>	9	WHI ROU	_	Size Imprint Code		6	64;339 Mark	eting End Date
Color Shape Flavor Contains Packagin # Item Co	g ode 10 in	Pa 1 CARTON	ND ckage Desc	Size Imprint Code		eting Start Date	64;339 Mark	
Color Shape Flavor Contains Packagin # Item Co 1 NDC:0054 8740-25	g ode 10 in	Pa 1 CARTON 1 BLISTEF	ND ckage Desc	Size Imprint Code		eting Start Date	64;339 Mark	
Color Shape Flavor Contains Packagin # Item Co 1 NDC:0054 8740-25	<b>g</b> ode 10 in 10 in	Pa 1 CARTON 1 BLISTEF	ND ckage Desc	Size Imprint Code		eting Start Date	64;339 Mark	
Color Shape Flavor Contains Packagin # Item Co 1 NDC:0054 8740-25	g ode 10 in 10 in Produ	Pa 1 CARTON 1 BLISTER	nD ckage Desc I R PACK; Type 0	Size Imprint Code		eting Start Date	64;339 Mark	
Color Shape Flavor Contains Packagin # Item Co	g ode 10 in 10 in Produ	Pa 1 CARTON 1 BLISTEF	ckage Deso kage Deso kapack; Type C	Size Imprint Code Imprint Code Not a Combination Not a Combination	04/22/19	eting Start Date	imm i4;339 Mark	

PREDNISONE prednisone tablet			
Product Information			
Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:0054-8724

Ac	tive Ingred	ient/Acti	ive Moiety					
Ingredient Name Basis of Strengt							Strength	
PR	PREDNISONE (UNII: VB0R961HZT) (PREDNISONE - UNII: VB0R961HZT) PREDNISONE					-	5 mg	
In	active Ingre	dients						
Ingredient Name							Strength	
LA	стоѕе молон	YDRATE (L	JNII: EWQ57Q8I5X)					
MA	GNESIUM STE	RATE (UNI	I: 70097M6I30)					
			OSE (UNII: OP1R32	D61U)				
	ARCH, CORN (U							
			Έ ΤΥΡΕ Α ΡΟΤΑΤΟ	(UNII: 5856J3G2A2)				
ST	EARIC ACID (UN	III: 4ELV7Z6	5AP)					
Pr	oduct Char	acteristi	cs					
Co	lor		WHITE	Score		2 pieces	2 pieces	
Sh	аре		ROUND	Size		6mm	nm	
Fla	avor			Imprint Code		54;612	54;612	
Co	ntains							
_								
Pa	ackaging							
#	ltem Code		Package Desc	ription	Marketing Star Date		eting End Date	
	NDC:0054-	10 in 1 CA	RTON		04/21/1972			
	8724-25				04/21/19/2			
			STER PACK; Type 0:	Not a Combination	04/21/19/2			
-		10 in 1 BLI		Not a Combination	04/21/15/2			
1		10 in 1 BLI Product	STER PACK; Type 0:	Not a Combination	04/21/15/2			
1	8724-25	10 in 1 BLI Product	STER PACK; Type 0:	or Monograph	Marketing Star Date	t Mark	ceting End Date	

Labeler - Hikma Pharmaceuticals USA Inc. (080189610)

Establishment								
Name	Address	ID/FEI	Business Operations					
West-Ward Columbus Inc.		058839929	MANUFACTURE(0054-4741, 0054-4742, 0054-4728, 0054-0017, 0054-0018, 0054-0019, 0054-3722, 0054-3721, 0054-8739, 0054-8740, 0054-8724)					

\_ \_\_ \_